By PPN News Staff
The FDA granted a new indication for dupilumab (Dupixent, Regeneron-Sanofi) to treat adults with nasal polyps accompanied by chronic rhinosinusitis. This is the first treatment approved for inadequately controlled chronic rhinosinusitis with nasal polyps.
Dupilumab is a fully human monoclonal antibody that inhibits the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that play a central role in type 2 inflammation. Data from clinical trials of dupilumab